Human Microbiome Therapeutics Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global human microbiome therapeutics market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the human microbiome therapeutics market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global human microbiome therapeutics market opportunities and strategies to 2030 report answers all these questions and many more.
The report covers the following chapters
Markets Covered: The global human microbiome therapeutics market is segmented by -
Companies Mentioned: Seres Therapeutics; Assembly Biosciences; Enterome Bioscience; Vedanta BioSciences; Second Genome Inc.
Countries: China, India, Japan, Australia, Indonesia, South Korea, USA, Brazil, France, Germany, UK, Russia
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Outperform competitors using accurate up to date demand-side dynamics information.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Identify growth segments for investment.
- Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
- Create regional and country strategies on the basis of local data and analysis.
- Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors.
- Develop strategies based on likely future developments.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Gain a global perspective on the development of the market.
Description:
Where is the largest and fastest growing market for the human microbiome therapeutics market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global human microbiome therapeutics market opportunities and strategies to 2030 report answers all these questions and many more.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives brief introduction about segmentation by geography and segmentation by disease, and by sequencing technology type.
- Market Characteristics - The market characteristics section of the report defines and explains the human microbiome therapeutics market. This chapter also defines and describes products covered in the report.
- Trends and Strategies - This chapter describes the major trends shaping the global human microbiome therapeutics market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Global Market Size and Growth - This section contains the global forecast (2023-2025), (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the forecast periods.
- Regional Analysis - This section contains the forecast (2023-2025), and (2025-2030) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2023-2030) and analysis for different segments.
- Regional Market Size and Growth - This section contains the region’s market size forecast (2023-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global human microbiome therapeutics market, estimated market shares and company profiles for the leading players.
- Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities and Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for human microbiome therapeutics companies in terms of product/service offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered: The global human microbiome therapeutics market is segmented by -
- By Disease: Infectious Diseases; Gastrointestinal Disorders; Metabolic Disorders; Cancers; Other Diseases
- By Sequencing Technology Type: Targeted Gene; RNA; Whole-Genome Shotgun (WGS); Others Types
Companies Mentioned: Seres Therapeutics; Assembly Biosciences; Enterome Bioscience; Vedanta BioSciences; Second Genome Inc.
Countries: China, India, Japan, Australia, Indonesia, South Korea, USA, Brazil, France, Germany, UK, Russia
Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Human Microbiome Therapeutics Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure9. COVID Impact Human Microbiome Therapeutics Market
6. Introduction
7. Human Microbiome Therapeutics Market Characteristics
8. Human Microbiome Therapeutics Market Trends and Strategies
10. Global Human Microbiome Therapeutics Market Size and Growth
11. Human Microbiome Therapeutics Market, Regional Analysis
12. Global Human Microbiome Therapeutics Market Segmentation
13. Asia-Pacific Human Microbiome Therapeutics Market
14. Western Europe Human Microbiome Therapeutics Market
15. Eastern Europe Human Microbiome Therapeutics Market
16. North America Human Microbiome Therapeutics Market
17. South America Human Microbiome Therapeutics Market
18. Middle East Human Microbiome Therapeutics Market
19. Africa Human Microbiome Therapeutics Market
20. Global Human Microbiome Therapeutics Market Competitive Landscape
21. Key Mergers and Acquisitions in The Human Microbiome Therapeutics Market
22. Human Microbiome Therapeutics Market Opportunities and Strategies
23. Microbiome Homes Market, Conclusions and Recommendations
24. Appendix
Executive Summary
This report describes and evaluates the global human microbiome therapeutics market in the forecast period. It covers the forecast period, 2023-2025 forecast period, and 2025-2030 the forecast period.The global human microbiome therapeutics market is expected to reach a value of nearly $148.6 million in 2025, having increased at a compound annual growth rate (CAGR) of 21.9% since 2023. The market is expected to increase from $148.6 million in 2025 to $400.0 million in 2030 having increasing at growth rate of 21.9%.
Growth is forecast period is expected to drive by increase in funding, increase in prevalence of chronic diseases and technological advances. Factors that could hinder the growth of the human microbiome therapeutics market in the future include ethical issues associated with the market.
The human microbiome therapeutics market is segmented disease into infectious diseases, gastrointestinal disorders, metabolic disorders, cancers and other diseases. The infectious diseases market was the largest segment of the human microbiome therapeutics market segmented by disease, accounting for 70.9% of the total in 2030. It is also expected to be the fastest growing segment in the human microbiome therapeutics market segmented by disease, at a CAGR of 15.7% during 2025-2030.
The human microbiome therapeutics market is also segmented by sequencing technology type into targeted gene, RNA, whole-genome sequencing (WGS) and others. The global RNA market was the largest segment of the human microbiome therapeutics market segmented by sequencing technology type, accounting for 32.5% of the total in 2023. Going forward, the whole genome shotgun segment is expected to be the fastest growing segment in the human microbiome therapeutics market segmented by sequencing technology type, going forward, at a CAGR of 18.2% during 2025-2030.
North America was the largest region in the global human microbiome therapeutics market, accounting for 52.8% of the total in 2030. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the human microbiome therapeutics market will be Asia Pacific and North America where growth will be at CAGRs of 47.4% and 21.6% respectively. These will be followed by Eastern Europe, and South America, where the markets are expected to grow at CAGRs of 19.3% and 15.6% respectively.
The global human microbiome therapeutics market is an emerging market. Top 10 players in the market include Seres Therapeutics, Assembly Biosciences, Enterome Bioscience, Vedanta BioSciences, Second Genome Inc., ViThera Pharmaceuticals Inc., Osel, Rebiotix, Inc., MicroBiome Therapeutics LLC and MaaT Pharma.
The top opportunities in the human microbiome therapeutics market segmented by disease will arise in the infectious disease segment, which will gain $183.5 million of global annual sales by 2030. The top opportunities in the human microbiome therapeutics market segmented by sequencing technology type will arise in the whole-genome shotgun market segment, which will gain $115.2 million of global annual sales by 2030.
Market-trend-based strategies for the human microbiome therapeutics market include investing in the strategic collaboration and research and development of microbiome therapeutics for treating cancers. Player-adopted strategies in the human microbiome therapeutics market include expanding through strategic collaborations.
The COVID-19 pandemic has decreased short-term potential growth opportunities for the microbiome industry.
To take advantage of the opportunities, the publisher recommends the microbiomes market companies to focus on strategic collaborations and agreements, focus on pipeline studies and drug development, focus on increasing investments for development of cancer microbiome therapeutics, establish operations in emerging markets, leverage online pharmacies, set up authorized distributors and sales representatives, provide competitively priced offerings in low-income countries to reach new users, offer skimmed pricing for innovative drugs, participate in trade shows and events, increase adoption of the internet and social media, target local pharmacies to spread awareness, focus on digestive health and focus on the increased requirement of R&D scientists
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Seres Therapeutics
- Assembly Biosciences
- Enterome Bioscience
- Vedanta BioSciences
- Second Genome Inc.
Methodology
LOADING...